Search Results

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report third quarter fiscal 2024 financial results after the market close on Tuesday, July 2, 2024.

Simulations Plus, Inc. announced the acquisition of Pro-ficiency Holdings, Inc. and its subsidiaries, a leader in providing simulation-enabled performance and intelligence solutions for clinical and commercial drug development.

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced that Shawn O’Connor, chief executive officer, will participate in Craig-Hallum’s 21st Annual Institutional Investor Conference on Wednesday, May 29, 2024, in Minneapolis, MN.

Simulations Plus, Inc. today announced that Shawn O’Connor, chief executive officer, will participate in the Morgan Stanley 3rd Annual Life Sciences AI Summit on Wednesday, June 26, 2024, at Morgan Stanley’s headquarters in New York City.

Simulations Plus, Inc. (NASDAQ: SLP) (“Simulations Plus”), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today reported financial results for its second quarter fiscal 2024, ended February 29, 2024.

Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), announced today that it will report second quarter fiscal 2024 financial results after the market close on Wednesday, April 3, 2024.

Simulations Plus, Inc. today announced that it will participate in two healthcare conferences in February.

Simulations Plus, Inc., a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, provided additional information on advancing its corporate allocation strategy, specifically increased focus on strategic investments and partnerships.

Simulations Plus, Inc. today announced the release of GastroPlus® 9.9, the latest version of its flagship physiologically based pharmacokinetics/biopharmaceutics (PBPK/PBBM) modeling and simulation software.

Simulations Plus, Inc. announced an extension to the formal agreement with the Translational Toxicology Division at the National Institute of Environmental Health Sciences to support the rapid safety assessment of chemicals in animals and humans.